医療科学部

Hideaki Matsuura

  (松浦 秀哲)

Profile Information

Affiliation
School of Health Sciences, Fujita Health University
Degree
博士(医学)(藤田保健衛生大学)

researchmap Member ID
B000339755

Papers

 35
  • Rie Nakagawa, Hideaki Matsuura, Hayato Kojima, Yuko Abe, Ayuna Yamada, Hiroki Doi, Yasuo Miura
    Laboratory medicine, Sep 22, 2024  Peer-reviewedCorresponding author
    BACKGROUND: Donor-specific antibodies (DSAs) targeting human leukocyte antigens (HLAs) substantially reduce the longevity of transplanted organs. Desensitization of DSA-positive renal transplant recipients is achieved through intravenous administration of immunoglobulin (IVIg). However, the presence and detectability of anti-HLA antibodies in IVIg preparations following administration are not fully understood. We aimed to assess whether immunoglobulin preparations contain anti-HLA antibodies that can be detected as passive antibodies when administered into the body. METHODS: We evaluated 3 immunoglobulin preparations from different pharmaceutical companies, using anti-HLA class I and II antibody specificity tests and immunocomplex capture fluorescence analysis (ICFA). RESULTS: Direct testing for anti-HLA antibodies resulted in high background errors, particularly for Venoglobulin. Diluting Venoglobulin to physiological concentrations revealed the presence of anti-HLA class I antibodies; however, no common alleles were found between the specificity identification test and ICFA.For Glovenin and Venilon, anti-HLA class I and II antibodies were detected; however, variability was observed across different test reagent lots. Moreover, dilution of the globulin formulation revealed a prozone phenomenon. CONCLUSION: The administration of IVIg complicates the accurate detection of anti-HLA antibodies, underscoring the need for careful interpretation of test results post-IVIg administration.
  • Chiaki Yamada, Takaaki Ono, Kaede Ino, Naoki Nemoto, Takahito Shinba, Hiroaki Furumaki, Hiroki Shibata, Keiko Ishizuka, Naotomo Yamada, Hideaki Matsuura, Yumiko Izuhara, Harumi Fujihara, Hitoshi Minamiguchi
    Transfusion, Sep 17, 2024  Peer-reviewed
    BACKGROUND: Despite several reports on red blood cell (RBC) alloimmunization, the actual prevalence and factors contributing to RBC alloimmunization in transfused patients remain poorly investigated. We examined the association between clinical factors and the development and evanescence of RBC antibodies after transfusion. STUDY DESIGN AND METHODS: Each participating institution performed antibody screens before and after RBC transfusion. A survey including patient characteristics, results of antibody screen and identification, antibody screen methods, total amount of RBC transfused, and adverse reactions, was conducted. RESULTS: Between October 2018 and March 2023, 1194 patients were registered at five institutions. Overall, 958 patients underwent at least one follow-up RBC antibody screen after transfusion, revealing new antibody development in 44 (4.6%). Anti-E was identified in 25 patients, anti-Jka in 5, and anti-c in 4. The number of RBC units transfused was significantly associated with antibody development after transfusion (p < .001). Among 55 patients in whom antibodies were identified after transfusion, including historical antibodies, antibodies evanesced in 18 (33%); anti-E in 7, anti-Jka in 4, and anti-Lea in 2. Evanescent antibodies were identified more frequently by saline and/or enzyme methods than persistent antibodies (p = .012). DISCUSSION: The number of RBC units transfused can impact antibody development, and antibodies identified only by saline and/or enzyme methods, deemed clinically insignificant, are likely to have a high evanescence rate. Antibody screen should be carefully performed, especially in those receiving a large number of RBC units. Confirming previous antibody screen results should be performed to prevent omitting evanesced antibodies regardless of clinical relevance.
  • YAMADA Ayuna, MATSUURA Hideaki, ABE Yuko, NAKAGAWA Rie, MIURA Yasuo
    Japanese Journal of Medical Technology, 73(1) 25-30, Jan 25, 2024  Peer-reviewedCorresponding author
    Severe coronavirus infection (COVID-19) requires treatment with extracorporeal membrane oxygenation (ECMO). COVID-19 patients have high transfusion requirements, but there are few reports on how to manage and administer them. From 2019 to 2021, 37 patients with COVID-19 and ischemic heart disease (IHD) were enrolled. We obtained information about the patients’ background features, blood product requirements, duration of ECMO, laboratory data, and outcomes. During ECMO, transfusion was administered in both groups at the time of laboratory data reduction and ECMO weaning. IHD patients were administered each blood product in the early phase of ECMO. In contrast, COVID-19 patients were administered blood products every day during ECMO and used significantly more FFP than IHD patients. Laboratory data are generally used as a guideline for transfusion therapy, but transfusions are also administered during weaning from ECMO, it is necessary to pay attention to the status of the treatment. We need to monitor laboratory data and treatment status to manage blood products and to quickly respond to transfusion requests.
  • Kato Shizuho, Hayashi Megumi, Ichikawa Jun, Futamura Ako, Katai Akiko, Matsuura Hideaki
    Japanese Journal of Transfusion and Cell Therapy, 69(6) 667-673, Dec 20, 2023  Peer-reviewedLast authorCorresponding author
  • Hideaki Matsuura, Sumie Fujii, Yasunori Ueda, Yasuo Miura
    Transfusion, 63(8) 1420-1422, Jun 8, 2023  Peer-reviewedLead author

Misc.

 124

Books and Other Publications

 4

Research Projects

 3
  • 科学研究費助成事業, 日本学術振興会, Apr, 2024 - Mar, 2027
    松浦 秀哲
  • 科学研究費助成事業, 日本学術振興会, Apr, 2021 - Mar, 2024
    松浦 秀哲
  • Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Japan Society for the Promotion of Science, Apr, 2016 - Mar, 2019
    Takeshita Akihiro, Oto Hitoshi, Watanabe Hiroko, Ishimaru Ken, Kawabata Kinuyo, Nomaguchi Yuriko, Haraguchi Yasue, Abe Misao, Sobue Koki, Takenouchi Hiroyuki, Takadate Junko, Kamimura Masami, Katai Akiko, Kasai Daisuke, Minami Yumiko, Sugimoto Tatsuya, Michino Junko, Nagai Kazuhiro, Kumagai Mikako, Hasegawa Yuichi, Sato Hidehiro, Takahashi Koki, Fujii Satoshi, Otomo Naoki, Yonemura Yuji, Yoshida Masaya, Nagamine Keisuke, Fujiwara Koki, Maruyama Mitsuko, Lee Etsuko, Yamada Naotomo, Hashimoto Makoto, Buseki Yuji, Hasegawa Mayumi, Matsuura Hideaki, Ishikawa Shinsuke, Tanaka Kazuto, Osawa Toshiya, Shinohara Shigeru, Tatsukawa Yoshiaki, Sato Genshiro, Nagamura Tokiko, Matsunami Misako, Okamoto Aya, Oda Nozomi, Kumano Yumiko, Asahina Aya, Nakagiri Itsuro, Kochi Noriyo

Other

 2